Cargando…

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases

BACKGROUND: The Living with Pulmonary Fibrosis (L-PF) questionnaire assesses symptoms and quality of life in patients with fibrosing interstitial lung diseases (ILDs). Its Dyspnoea and Cough domains, whose items’ responses are based on a 24-hour recall, have scores ranging from 0 to 100, with higher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swigris, Jeffrey J, Bushnell, Donald M, Rohr, Klaus, Mueller, Heiko, Baldwin, Michael, Inoue, Yoshikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896030/ https://www.ncbi.nlm.nih.gov/pubmed/35241434 http://dx.doi.org/10.1136/bmjresp-2021-001167

Ejemplares similares

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
por: Birring, Surinder S., et al.
Publicado: (2022)

Reliability and responsiveness of the D12 and validity of its scores as a measure of dyspnoea severity in patients with rheumatoid arthritis-related interstitial lung disease
por: Swigris, Jeffrey J, et al.
Publicado: (2023)

Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases
por: Salonen, Johanna, et al.
Publicado: (2020)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin
por: Arai, Toru, et al.
Publicado: (2021)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial
por: Arai, Toru, et al.
Publicado: (2020)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Feasibility of cardiopulmonary exercise testing in interstitial lung disease: the PETFIB study
por: Tomlinson, Owen, et al.
Publicado: (2021)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians
por: Althobiani, Malik, et al.
Publicado: (2021)

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
por: Shah Gupta, Rikisha, et al.
Publicado: (2023)

Predictors of postoperative acute exacerbation of interstitial lung disease: a case–control study
por: Hosoki, Keisuke, et al.
Publicado: (2020)

Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
por: Upperton, Sara, et al.
Publicado: (2023)

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study
por: Mandizha, Jessica, et al.
Publicado: (2023)

Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey
por: Case, Amy Hajari, et al.
Publicado: (2023)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021)

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis
por: Nayebirad, Sepehr, et al.
Publicado: (2023)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
por: Aoshima, Yoichiro, et al.
Publicado: (2021)

In vivo polarisation sensitive optical coherence tomography for fibrosis assessment in interstitial lung disease: a prospective, exploratory, observational study
por: Vaselli, Margherita, et al.
Publicado: (2023)

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2021)

Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs
por: Barratt, Shaney L, et al.
Publicado: (2018)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dkmd8id9uj5ge500a4o02i2vcm